Inactivated Influenza Vaccine Global Market Report 2025

The inactivated influenza vaccine market size has grown strongly in recent years. It will grow from$6.62 billion in 2024 to $7.21 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth during the historic period can be attributed to increased seasonal influenza outbreaks, government vaccination campaigns, a rising elderly population, improved public health awareness, and the expansion of healthcare infrastructure.

The inactivated influenza vaccine market size is expected to see strong growth in the next few years. It will grow to$9.99 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to the rising demand for quadrivalent vaccines, the expansion of immunization programs, a growing focus on pandemic preparedness, technological advancements in vaccine production, and increasing global access to vaccines. Key trends during this period include a shift toward cell-based vaccine production, the growing adoption of adjuvanted formulations, the integration of influenza vaccines with COVID-19 boosters, rising demand in emerging markets, and the development of personalized vaccine strategies.

The growth of government vaccination programs is significantly boosting the inactivated influenza vaccine market. As public health awareness increases, governments are enhancing their immunization efforts, leading to greater demand for vaccines and more accessible immunization services. These programs play a critical role in providing free or subsidized inactivated influenza vaccines to high-risk groups, ensuring widespread vaccine coverage, and reducing the seasonal burden of influenza. For example, in December 2023, the UK’s National Health Service (NHS) introduced a new vaccination strategy aimed at improving immunization outreach, particularly to underserved and marginalized communities. This strategy is designed to expand vaccination accessibility and further promote public health, which in turn is expected to drive growth in the inactivated influenza vaccine market.

Leading companies in the inactivated influenza vaccine market are increasingly focusing on the development of quadrivalent vaccines. These vaccines are designed to protect against four distinct strains of the influenza virus, offering broader protection and improving vaccine efficacy. For example, in February 2025, Zydus Lifesciences, an India-based pharmaceutical company, launched VaxiFlu-4, a quadrivalent inactivated influenza vaccine that provides protection against four strains of the flu virus. By covering both influenza A and B strains, this vaccine reduces the risk of vaccine mismatch and enhances protection against seasonal flu outbreaks, while also tailoring immune responses to regional epidemiological trends.

In July 2024, GSK plc, a UK-based pharmaceutical company, expanded its capabilities in mRNA vaccine development by acquiring the full rights to develop, manufacture, and commercialize mRNA-based influenza and COVID-19 vaccines from CureVac N.V. for an undisclosed amount. This acquisition allows GSK to leverage CureVac’s advanced mRNA research to improve seasonal flu vaccines and boost pandemic preparedness strategies. CureVac, a Germany-based biotechnology company, specializes in mRNA-based therapeutics, including vaccines for influenza and cancer immunotherapy.

Major players in the inactivated influenza vaccine market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Novartis International, GlaxoSmithKline plc, Viatris Inc., CSL, Zydus Lifesciences Limited, Sinovac Biotech Ltd., Bharat Biotech International Limited, Dalian Aleph Biomedical Co. Ltd., Hualan Biological Bacterin Co. Ltd, Changchun Biological, Jiangsu gdk Biotechnology Co., Ltd., KM Biologics, JoinHub Pharma, and Pharmika India Private Limited.

North America was the largest region in the inactivated influenza vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated influenza vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the inactivated influenza vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Inactivated influenza vaccines are flu vaccines that contain viruses that have been killed or inactivated. These vaccines stimulate the immune system to produce antibodies against the influenza virus and are administered via injection to help prevent seasonal influenza infections.

The main types of vaccines in the inactivated influenza vaccine market include the trivalent inactivated influenza vaccine (TIIV) and the quadrivalent inactivated influenza vaccine (QIIV). The trivalent inactivated influenza vaccine contains three inactivated virus strains two influenza A strains and one influenza B strain to provide protection against seasonal influenza. These vaccines are used across various age groups, including children, adolescents, adults, and the elderly, and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and public health clinics. End users include healthcare providers, individuals, government organizations, and pharmaceutical companies.

The inactivated influenza vaccine market research report is one of a series of new reports that provides inactivated influenza vaccine market statistics, including inactivated influenza vaccine industry global market size, regional shares, competitors with an inactivated influenza vaccine market share, detailed inactivated influenza vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the inactivated influenza vaccine industry. This inactivated influenza vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The inactivated influenza vaccine market consists of sales of adjuvanted inactivated influenza vaccines, preservative-free inactivated influenza vaccines, cell-based inactivated influenza vaccines, egg-based inactivated influenza vaccines, pediatric inactivated influenza vaccines, high-dose inactivated influenza vaccines for older adults, prefilled syringe vaccines, and multidose vial vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.